1. H. Selye, “Selye’s Guide to Stress
Research,” Van Nostrand Reinhold, New York, 1990.
2. S.R. Burchfield, “The stress
response: a new perspective,” Psychosomatic Medicine 41 (1979): 661-672.
3. W. Vale, J. Spiess, C. Rivier, and J. Rivier,
“Characterization of a 41-residue ovine hypothalamic peptide that stimulates
the secretion of corticotropin and
-endorphin,” Science 213
4. R.P. Rao, S. Anilkumar, B.S. McEwen,
and S. Chattarji. “Glucocorticoids protect against the delayed behavioral and
cellular effects of acute stress on the amygdala.” Biological Psychiatry 72 (2012) 466-475.
5. G.F. Koob, and M. Le Moal, “Addiction and the brain
antireward system,” Annual Review of Psychology 59 (2008): 29-53.
6. J.E. LeDoux, “Emotion circuits in the brain,” Annual
Review of Neuroscience23 (2000): 155-184.
7. G.F. Alheid, and L. Heimer, “New perspectives in basal
forebrain organization of special relevance for neuropsychiatric disorders: the
striatopallidal, amygdaloid, and corticopetal components of substantia
innominata,” Neuroscience 27 (1988): 1-39.
8. S.M. Reynolds, S. Geisler, A. Bérod, and D.S. Zahm.
“Neurotensin antagonist acutely and robustly attenuates locomotion that
accompanies stimulation of a neurotensin-containing pathway from rostrobasal
forebrain to the ventral tegmental area.” European Journal of Neuroscience 24
9. L.M. Shin, and I. Liberzon, “The neurocircuitry of fear,
stress, and anxiety disorders,” Neuropsychopharmacology 35 (2010): 169-191.
10. G.F. Koob, “Neuroadaptive mechanisms
of addiction: studies on the extended amygdala,” European
Neuropsychopharmacology 13 (2003): 442-452.
11. R.E. Sutton, G.F. Koob, M. Le Moal, J.
Rivier, and W. Vale, “Corticotropin releasing factor produces behavioural
activation in rats,” Nature 297 (1982): 331-333
12. G.F. Koob, and E.P. Zorrilla,
“Neurobiological mechanisms of addiction: focus on corticotropin-releasing
factor,” Current Opinion in Investigational Drugs 11 (2010): 63-71.
13. A. Van’t Veer A, and W.A. Carlezon,
Jr., “Role of kappa-opioid receptors in stress and anxiety-related behavior,”
Psychopharmacology 229 (2013): 435-452.
14. S.J. Watson, H. Khachaturian, H. Akil,
D.H. Coy, and A. Goldstein, “Comparison of the distribution of dynorphin
systems and enkephalin systems in brain,” Science 218 (1982): 1134-1136.
15. J. H. Fallon, and F.M. Leslie,
“Distribution of dynorphin and enkephalin peptides in the rat brain,” Journal
of Comparative Neurology 249 (1986): 293-336.
16. G.F. Koob,
“The dark side of emotion: the addiction perspective,” European Journal of Pharmacology (2014) in
17. P. Ouimette, J. Read, and P.J. Brown,
“Consistency of retrospective reports of DSM-IV Criterion A traumatic stressors
among substance use disorder patients,” Journal of Traumatic Stress 18 (2005):
18. C. Herry, F. Ferraguti, N. Singewald,
J.J. Letzkus, I. Ehrlich, and A. Luthi, “Neuronal circuits of fear extinction,”
European Journal of Neuroscience 31 (2010): 599-612.
19. R. Yehuda, “Status of glucocorticoid
alterations in post-traumatic stress disorder,” Annals of the New York Academy
of Sciences 1179 (2009): 56-69.
20. M. Van Zuiden, E. Geuze, H.L.
Willermen, E. Vermetten, M. Maas, C.J. Heijnen, and A. Kavelaars, “Pre-existing
high glucocorticoid receptor number predicting development of posttraumatic
stress symptoms after military deployment,” American Journal of Psychiatry 168
21. V.B Risbrough, and M.B. Stein, “Role
of corticotropin releasing factor in anxiety disorders: a translational research perspective,”
Hormones and Behavior 50 (2006): 550-561.
22. D.G. Baker, S.A. West, W.E. Nicholson,
N.N. Ekhator, J.W. Kasckow, K.K. Hill, A.B. Bruce, D.N. Orth, and T.D.
Geracioti, “Serial CSF CRH levels and adrenocortical activity in combat
veterans with posttraumatic stress disorder,” American Journal of Psychiatry, 156
23. R.H. Pietrzak, M. Naganawa, Y. Huang,
S. Corsi-Travali, M.Q. Zheng, M.B. Stein, S. Henry, K. Lim, J. Ropchan, S.F.
Lin, R.E. Carson, and A. Neumeister, “Association of in vivo
availability and the transdiagnostic dimensional expression of trauma-related
psychopathology,” JAMA Psychiatry 71 (2014): 1262-1270.
24. J.P. Hayes, S.M. Hayes, and A.M.
Mikedis, “Quantitative meta-analysis of neural activity in posttraumatic stress
disorder,” Biology of Mood and Anxiety Disorders 2 (2012): 9.
25. S.L. Rauch, L.M. Shin, and E.A.
Phelps, “Neurocircuitry models of posttraumatic stress disorder and extinction:
human neuroimaging research: past, present, and future,” Biological Psychiatry
60 (2006): 376-382.
26. R.K. Pitman, A.M. Rasmusson, K.C.
Koenen, L.M. Shin, S.P. Orr, M.W. Gilbertson, M.R. Milad, and I. Liberzon,
“Biological studies of post-traumatic stress disorder,” Nature Reviews
Neuroscience 13 (2012): 769-787.
27. M.R. Milad, G.J. Quirk, R.K. Pitman,
S.P. Orr, B. Fischl, and S.L. Rauch, “A role for the human dorsal anterior
cingulate cortex in fear expression,” Biological Psychiatry 62 (2007a):
28. M.R. Milad, C.I. Wright, S.P. Orr,
R.K. Pitman, G.J. Quirk, and S.L. Rauch, “Recall of fear extinction in humans activates
the ventromedial prefrontal cortex and hippocampus in concert,” Biological
Psychiatry 62 (2007b): 446-454.
29. G.F. Koob, and M. Le Moal, “Drug
abuse: hedonic homeostatic dysregulation,” Science 278 (1997): 52-58.
30. G.F. Koob, and N.D. Volkow, “Neurocircuitry
of addiction,” Neuropsychopharmacology Reviews 35 (2010): 217-238.
31. F.J. Vaccarino, H.O. Pettit, F.E.
Bloom, and G.F. Koob. “Effects of intracerebroventricular administration of
methyl naloxonium chloride on heroin self-administration in the rat.”
Pharmacology Biochemistry and Behavior 23 (1985): 495-498.
32. N.D. Volkow, G.J. Wang, F. Telang,
J.S. Fowler, J. Logan , M. Jayne, Y. Ma, K. Pradhan, and C. Wong, “Profound
decreases in dopamine release in striatum in detoxified alcoholics: possible
orbitofrontal involvement,” Journal of Neuroscience 27 (2007): 12700-12706.
33. J.M. Mitchell, J.P. O’Neil, M. Janabi,
S.M. Marks, W.J. Jagust, and H.L. Fields, “Alcohol consumption induces
endogenous opioid release in the human orbitofrontal cortex and nucleus
accumbens,” Science Translational Medicine 4 (2012): 116ra6.
34. S.B. Sparber, and D.R. Meyer,
“Clonidine antagonizes naloxone-induced suppression of conditioned behavior and
body weight loss in morphine-dependent rats,” Pharmacology Biochemistry and
Behavior 9 (1978): 319-325.
35. G.F. Koob, T.L. Wall, and F.E. Bloom,
“Nucleus accumbens as a substrate for the aversive stimulus effects of opiate
withdrawal,” Psychopharmacology 98 (1989): 530-534.
36. G.F. Koob, and M. Le Moal, “Drug
addiction, dysregulation of reward, and allostasis,” Neuropsychopharmacology,
24 (2001): 97-129.
37. W.A. Carlezon, Jr., E.J. Nestler, and
R.L. Neve, “Herpes simplex virus-mediated gene transfer as a tool for
neuropsychiatric research,” Critical Reviews in Neurobiology 14 (2000): 47-67.
38. H.A. Baldwin, S. Rassnick, J. Rivier,
G.F. Koob, and K.T. Britton, “CRF antagonist reverses the “anxiogenic” response
to ethanol withdrawal in the rat,” Psychopharmacology 103 (1991): 227-232.
39. E. Merlo-Pich, M. Lorang, M. Yeganeh,
F. Rodriguez de Fonseca, J. Raber, G.F. Koob, and F. Weiss, “Increase of
extracellular corticotropin-releasing factor-like immunoreactivity levels in
the amygdala of awake rats during restraint stress and ethanol withdrawal as
measured by microdialysis,” Journal of Neuroscience 15 (1995): 5439-5447.
40. C.K. Funk, L.E. O’Dell, E.F. Crawford,
and G.F. Koob, “Corticotropin-releasing factor within the central nucleus of
the amygdala mediates enhanced ethanol self-administration in withdrawn,
ethanol-dependent rats,” Journal of Neuroscience 26 (2006): 11324-11332.
41. L.F. Vendruscolo, E. Barbier, J.E.
Schlosburg, K.K. Misra, T. Whitfield, Jr., M.L. Logrip, C.L. Rivier, V.
Repunte-Canonigo, E.P. Zorrilla, P.P. Sanna, M. Heilig, and G.F. Koob.
“Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in
rats.” Journal of Neuroscience 32
42. B.M. Walker, E.P. Zorrilla, and G.F.
-opioid receptor antagonism by
nor-binaltorphimine reduces dependence-induced excessive alcohol
self-administration in rats,” Addiction Biology 16 (2010): 116-119.
43. S. Wee, L. Orio, S. Ghirmai, J.R.
Cashman, and G.F. Koob, “Inhibition of kappa opioid receptors attenuated
increased cocaine intake in rats with extended access to cocaine,”
Psychopharmacology 205 (2009): 565-575.
Whitfield, Jr., J. Schlosburg, S. Wee, L. Vendruscolo, A. Gould, O. George, Y.
Grant, S. Edwards, E. Crawford, and G. Koob, “Kappa opioid receptors in the
nucleus accumbens shell mediate escalation of methamphetamine intake,” Journal
of Neuroscience (2014) in press.
45. J.E. Schlosburg, T.W. Whitfield, Jr.,
P.E. Park, E.F. Crawford, O. George, L.F. Vendruscolo, and G.F. Koob.
“Long-term antagonism of κ opioid receptors prevents escalation of and increased
motivation for heroin intake.” Journal of Neuroscience 33 (2013): 19384-19392.
46. G.F. Koob,
reinforcement in drug addiction: the darkness within,” Current Opinion in
Neurobiology 23 (2013): 559-563.
47. O. George, C. Sanders, J. Freiling, E.
Grigoryan, C.D. Vu, S. Allen, E. Crawford, C.D. Mandyam, and G.F. Koob,
“Recruitment of medial prefrontal cortex neurons during alcohol withdrawal
predicts cognitive impairment and excessive alcohol drinking,” Proceedings of
the National Academy of Sciences of the United States of America 109 (2012):
48. J.L. Perry, J.E. Joseph, Y. Jiang,
R.S. Zimmerman, T.H. Kelly, M. Darna, P. Huettl, L.P. Dwoskin, and M.T. Bardo.
“Prefrontal cortex and drug abuse vulnerability: translation to prevention and
treatment interventions.” Brain Research Reviews 65 (2011): 124-149.
49. A. Etkin, K.C. Klemenhagen, J.T.
Dudman, M.T. Rogan, R. Hen, E.R. Kandel, and J. Hirsch, “Individual differences
in trait anxiety predict the response of the basolateral amygdala to unconsciously
processed fearful faces,” Neuron 44
50. A.R. Childress, P.D. Mozley, W.
McElgin, J. Fitzgerald, M. Reivich, and C.P. O’Brien, “Limbic activation during
cue-induced cocaine craving,” American Journal of Psychiatry 156 (1999): 11-18.
51. A. Sekiguchi, M. Sugiura, Y. Taki, Y.
Kotozaki, R. Nouchi, H. Takeuchi, T. Araki, S. Hanawa, S. Nakagawa, C.M.
Miyauchi, A. Sakuma,
and R. Kawashima, “Brain
structural changes as vulnerability factors and acquired signs of
post-earthquake stress,” Molecular Psychiatry 18 (2013): 618-623.
52. K. Felmingham, A. Kemp, L. Williams,
P. Das, G. Hughes, A. Peduto, and R. Bryant, “Changes in anterior cingulate and
amygdala after cognitive behavior therapy of posttraumatic stress disorder,”
Psychological Science 18 (2007): 127-129.
53. L.M. Shin, N.B, Lasko, M.L. Macklin,
R.D. Karpf, M.R. Milad, S.P. Orr, J.M. Goetz, A.J. Fischman, S.L. Rauch, and
R.K. Pitman, “Resting metabolic activity in the cingulate cortex and
vulnerability to posttraumatic stress disorder,” Archives of General Psychiatry
66 (2009): 1099-1107.
54. M. Uddin, A.E. Aiello, D.E. Wildman,
K.C. Koenen, G. Pawelec, R. de Los Santos, E. Goldmann, and S. Galea,
“Epigenetic and immune function profiles associated with posttraumatic stress disorder,”
Proceedings of the National Academy of Sciences of the United States of America
107 (2010): 9470-9475.
55. S.C. Pandey, R. Ugale, H. Zhang, L.
Tang, and A. Prakash, “Brain chromatin remodeling: a novel mechanism of alcoholism,” Journal of
Neuroscience 28 (2008): 3729-3737.
56. K.C. Koenen, M. Uddin, S.C. Chang,
A.E. Aiello, D.E. Wildman, E. Goldmann, and S. Galea, “SLC6A4 methylation
modifies the effect of the number of traumatic events on risk for posttraumatic
stress disorder,” Depression and Anxiety 28 (2011): 639-647.
57. S. Moonat, A.J. Sakharkar, H. Zhang,
L. Tang, and S.C. Pandey, “Aberrant histone deacetylase2-mediated histone
modifications and synaptic plasticity in the amygdala predisposes to anxiety
and alcoholism,” Biological Psychiatry 73 (2013): 763-773.